Kapur S, Seeman P
Schizophrenia Program and the PET Centre of the Centre for Addiction and Mental Health, University of Toronto, Canada.
Am J Psychiatry. 2001 Mar;158(3):360-9. doi: 10.1176/appi.ajp.158.3.360.
Although atypical antipsychotics are becoming the treatment of choice for schizophrenia, what makes an antipsychotic "atypical" is not clear. This article provides a new hypothesis about the mechanism of action of atypical antipsychotics.
Published data regarding the molecular, animal model, neuroimaging, and clinical aspects of typical and atypical antipsychotics were reviewed to develop this hypothesis. Particular attention was paid to data regarding the role of the serotonin 5-HT(2) and dopamine D(4) receptors in atypicality.
Neuroimaging data show that optimal dopamine D(2) occupancy is sufficient to produce the atypical antipsychotic effect. Freedom from motor side effects results from low D(2) occupancy, not from high 5-HT(2) occupancy. If D(2) occupancy is excessive, atypicality is lost even in the presence of high 5-HT(2) occupancy. Animal data show that a rapid dissociation from the D(2) receptor at a molecular level produces the atypical antipsychotic effect. In vitro data show that the single most powerful predictor of atypicality for the current generation of atypical antipsychotics is fast dissociation from the D(2) receptor, not its high affinity at 5-HT(2), D(4), or another receptor.
The authors propose that fast dissociation from the D(2) receptor makes an antipsychotic more accommodating of physiological dopamine transmission, permitting an antipsychotic effect without motor side effects, prolactin elevation, or secondary negative symptoms. In contrast to the multireceptor hypotheses, the authors predict that the atypical antipsychotic effect can be produced by appropriate modulation of the D(2) receptor alone; the blockade of other receptors is neither necessary nor sufficient.
尽管非典型抗精神病药物正成为治疗精神分裂症的首选药物,但使一种抗精神病药物具有“非典型性”的原因尚不清楚。本文提出了一个关于非典型抗精神病药物作用机制的新假说。
回顾了有关典型和非典型抗精神病药物的分子、动物模型、神经影像学及临床方面的已发表数据,以形成这一假说。特别关注了5-羟色胺5-HT(2)和多巴胺D(4)受体在非典型性方面作用的数据。
神经影像学数据表明,最佳的多巴胺D(2)占有率足以产生非典型抗精神病药物效应。无运动副作用是由于低D(2)占有率,而非高5-HT(2)占有率。如果D(2)占有率过高,即使存在高5-HT(2)占有率,非典型性也会丧失。动物数据表明,在分子水平上与D(2)受体的快速解离产生非典型抗精神病药物效应。体外数据表明,对于当前一代非典型抗精神病药物,非典型性的最有力单一预测指标是与D(2)受体的快速解离,而非其在5-HT(2)、D(4)或其他受体上的高亲和力。
作者提出,与D(2)受体的快速解离使抗精神病药物更能适应生理性多巴胺传递,从而在无运动副作用、催乳素升高或继发性阴性症状的情况下产生抗精神病药物效应。与多受体假说相反,作者预测,仅通过对D(2)受体的适当调节就能产生非典型抗精神病药物效应;阻断其他受体既非必要条件也非充分条件。